AIM ImmunoTech Says Overall Survival Analysis In Phase 2 Pancreatic Cancer Trial To Begin In Q3 2027; Reiterates Q1 2027 Topline Data
Share
Why It Matters
AIM ImmunoTech is testing a pancreatic cancer medicine. They will share early results in early 2027 and full results later that year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.